Emerging Science for the Treatment of Parkinson’s Disease


Program Dates: July 2, 2019 - July 1, 2020
Credits: 1.25 AMA PRA Category 1 Credits™


Emerging Science for the Treatment of Parkinson’s Disease

Program Overview

This CME activity will review emerging science for the treatment Parkinson’s disease (PD) as presented at the American Academy of Neurology (AAN) 2019 Annual Meeting in Philadelphia, Pennsylvania. The expert faculty, led by Dr. Daniel Kremens, will review the pathophysiology of Parkinson’s disease in order to diagnose patients early and accurately. The faculty will also analyze the latest clinical trial data for PD therapeutics, including data presented at the American Academy of Neurology 2019 Annual Meeting. Lastly, a discussion on how to implement the interprofessional team to develop individualized treatment strategies to improve outcomes for patients with Parkinson’s disease will be had. Upon completion of this educational activity, learners will gain insight on current therapeutic options to utilize when treating, managing and diagnosing patients.

Target Audience

Neurologists, internists, nurse practitioners, nurses, physician assistants and other healthcare providers involved in the management of patients with Parkinson’s disease

Learning Objectives

  1. Understand the pathophysiology of Parkinson’s disease to be able to diagnose patients early and accurately
  2. Analyze the latest clinical trial data for Parkinson’s disease therapeutics, including information presented at AAN 2019, for informed decision making
  3. Develop individualized treatment strategies with the interprofessional team to improve outcomes for patients with Parkinson’s disease

Faculty

Daniel Kremens, MD, JD, FAAN
Associate Professor of Neurology
Sidney Kimmel Medical College at Jefferson University
Co-Director of the Parkinson’s Disease and Movement Disorders Division
Neurology Clerkship Director
Sidney Kimmel Medical College at Jefferson University
Philadelphia, Pennsylvania

 

Stuart Isaacson, MD
Parkinson’s Disease and Movement Disorders Center of Boca Raton
Associate Professor of Neurology
FIU Herbert Wertheim College of Medicine
Boca Raton, Florida

 

 

Rajesh Pahwa, MD, FAAN, FANA
Professor, Movement Disorders Division Chief
University of Kansas Medical Center
Kansas City, Kansas

 

 

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

FacultyRelationship Identified With:
Daniel Kremens, MD, JD, FAANConsultant/Advisor: AbbVie; Acadia; Acorda; Adamas; Allergan; Britannia; GE Healthcare; Impax; Kyowa; Lundbeck; Merz; Neurocrine; St. Jude Medical; Sunovion; Teva; UCB; US WorldMeds

Grant/Research Support: Acorda; Cala Health; Enterin; Revance

Speaker’s Bureau: Acadia; Adamas; Impax; Lundbeck; Teva; UCB; US WorldMeds

Stuart Isaacson, MD

 

Consultant/Advisor: AbbVie; Acadia; Acorda; Adamas; Addex; Allergan; Amarantus; Axovant; Benevolent; Biogen; Britannia; Cerecor; Eli Lilly; Enterin; GE Healthcare; Global Kinetics; Impax; Intec; Ipsen; Jazz; Kyowa; Lundbeck; Michael J. Fox Foundation; Neurocrine; NeuroDerm; Parkinson Study Group; PharmaTwoB; Roche; Sanofi; Sunovion; Teva; Theravance; UCB; US World Meds; Zambon

Grant/Research Support: AbbVie; Acadia; Acorda; Adamas; Addex; Allergan; Amarantus; Axovant; Benevolent; Biogen; Britannia; Cerecor; Eli Lilly; Enterin; GE Healthcare; Global Kinetics; Impax; Intec; Ipsen; Jazz; Kyowa; Lundbeck; Michael J. Fox Foundation; Neurocrine; NeuroDerm; Parkinson Study Group; PharmaTwoB; Roche; Sanofi; Sunovion; Teva; Theravance; UCB; US World Meds; Zambon

Speaker’s Bureau: AbbVie; Acadia; Acorda; Adamas; Addex; Allergan; Amarantus; Axovant; Benevolent; Biogen; Britannia; Cerecor; Eli Lilly; Enterin; GE Healthcare; Global Kinetics; Impax; Intec; Ipsen; Jazz; Kyowa; Lundbeck; Michael J. Fox Foundation; Neurocrine; NeuroDerm; Parkinson Study Group; PharmaTwoB; Roche; Sanofi; Sunovion; Teva; Theravance; UCB; US World Meds; Zambon

Rajesh Pahwa, MD, FAAN, FANAConsultant/Advisor: Abbott; AbbVie; ACADIA; Acorda; Adamas; CALA; Global Kinetics; Lundbeck; Neurocrine; PhotoPharmics; Prilenia; Sunovion; Teva Neuroscience; US World Meds

Grant/Research Support: Abbott; AbbVie; Acorda; Biogen; Boston Scientific; Cala Health; Cavion; Cynapsus; Intec; Jazz; Kyowa; Lilly; NIH/NINDS; NPF; PSG; Roche; Sunovion; Theranexus; Theravance; US WorldMeds Voyager

Planners, Managers and Reviewers

Timothy Hayes, MD, PhD; Nicole Brestowski; Chelsey Benedek and Devon Dietzel hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

JointIn support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Biogen.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
  • CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
  • CME and CNE credit will be issued appropriate certificate of completion.
  • Others may request a “certificate of completion”.
  1. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CME inquiries or special needs, please contact [email protected].

BUTTON

 

Provided by: AcademicCME-web